Form 4: Director Sue-Jean Lin Sells Arcutis Shares
Statement of Changes in Beneficial Ownership
Director Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics, Inc. (ARQT) pursuant to a 10b5-1 trading plan.
Summary
- Director Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics common stock on June 15, 2026.
- The shares were sold at a weighted average price of $24.3807 per share.
- The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on December 4, 2025.
- Following the sale, the reporting person retains beneficial ownership of 27,567 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is a standard administrative procedure for insiders.
Positives
- The sale was conducted via a pre-planned 10b5-1 trading plan, which typically indicates the transaction is not based on non-public information.
Negatives
- Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock appreciation.
Risks
- The reporting person's 10b5-1 plan remains active until February 19, 2027, which may result in further periodic sales of company stock.
Future Outlook
The filing does not provide forward-looking business guidance, as it is a disclosure of insider transaction activity.
Industry Context
StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice and generally does not signal a change in company fundamentals or strategic direction.
Comparison to Industry Standards
- The use of 10b5-1 plans is the industry standard for directors and executives to liquidate equity positions while maintaining compliance with SEC insider trading regulations.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.
Next Steps
- Continued monitoring of future Form 4 filings to track the progress of the 10b5-1 trading plan through February 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-12-04 | Date the 10b5-1 trading plan was adopted. |
| 2026-06-15 | Date of the reported stock sale transaction. |
| 2026-06-17 | Date the Form 4 was signed and filed. |
| 2027-02-19 | Scheduled end date for the 10b5-1 trading plan. |
Keywords
ARQT, Arcutis Biotherapeutics, Insider Trading, Form 4, Director Sale, 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.